Skip to content
    3B Future Health Fund logo

    3B Future Health Fund

    Luxembourg City, LuxembourgFounded 2016
    3bfuturehealth.comLinkedIn
    Biotech & Life SciencesHealthcare

    3B Future Health Fund is a venture capital fund (formerly Helsinn Investment Fund) backed by the Helsinn Group and the Braglia family, investing in early-stage healthcare and life sciences companies with a focus on oncology and rare diseases across Europe and the US. Its latest fund (Fund II) targets €100 million to advance promising projects from preclinical stage to the clinic and beyond.

    50% of their portfolio is in Biotech & Life Sciences. Deal activity decreased year-over-year (1 deal in the last 12 months vs 3 prior). Their most common stage is series-b (47% of deals). Average disclosed round size is $31.6M (across 14 rounds with reported amounts).

    Find people at 3B Future Health Fund on Goldilocks AI

    Portfolio

    19

    Fund Size

    $108M

    Top Stage

    Series B

    Last 12 Mo

    1

    Team

    Alessandro Santoboni

    Alessandro Santoboni

    Managing Director and General Partner

    Francesco Giavatto MBA

    Francesco Giavatto MBA

    Chief Financial Officer and General Partner

    Marianne Bjordal PhD, MBA

    Marianne Bjordal PhD, MBA

    General Partner

    Riccardo Braglia MBA

    Riccardo Braglia MBA

    Chairman and General Partner

    Roberto De Ponti PharmD

    Roberto De Ponti PharmD

    General Partner

    Portfolio Breakdown

    Stage Distribution

    Sector Distribution

    Investment Activity

    DealsAvg Round Size

    Portfolio

    30 investments
    CompanyRoundAmountDate
    Kainova Therapeutics logoKainova TherapeuticsSeries B—Feb 2026
    Fore Biotherapeutics logoFore BiotherapeuticsSeries D$38MMay 2025
    FFore BioSeries D$38MMay 2025
    FFore BioSeries C$57MJan 2025
    Epsilogen Ltd logoEpsilogen LtdSeries B—Sep 2024
    iOnctura logoiOncturaSeries B—Jun 2024
    NeoPhore logoNeoPhoreSeries B—Feb 2024
    Epsilogen Ltd logoEpsilogen LtdSeries B—Jan 2024
    On Target Labs logoOn Target LabsSeries C$30MNov 2023
    OOn Target LaboratoriesSeries C$30MNov 2023
    OncoResponse logoOncoResponseSeries D$13MMay 2023
    SibYlla logoSibYllaSeries A—Oct 2022
    Sibylla Biotech logoSibylla BiotechSeries A—Oct 2022
    Domain Therapeutics logoDomain TherapeuticsSeries A$42MMay 2022
    Sibylla Biotech logoSibylla BiotechSeries A—Jan 2022
    Domain Therapeutics logoDomain TherapeuticsSeries A$42MJan 2022
    Roca Therapeutics logoRoca TherapeuticsSeed—Jan 2022
    Kainova Therapeutics logoKainova TherapeuticsSeries A$42MJan 2022
    GreenBone Ortho logoGreenBone OrthoSeries B—Apr 2021
    NeoPhore logoNeoPhoreSeries B—Jan 2021
    OncoResponse, Inc. logoOncoResponse, Inc.Series C$40.6MJan 2021
    OncoResponse logoOncoResponseSeries C$40.6MJan 2021
    GreenBone Ortho logoGreenBone OrthoSeries B—Jan 2021
    Greenbone logoGreenboneSeries B—Jan 2021
    Gain Therapeutics logoGain TherapeuticsSeries B$10MJul 2020
    Page 1 of 2

    Top Co-Investors

    Schroders Capital5 shared
    CDP Venture Capital5 shared
    Panacea Venture4 shared
    Viva BioInnovator4 shared
    Turenne Capital4 shared
    adMare BioInnovations4 shared
    Vi Partners4 shared
    Novartis Venture Fund4 shared
    Meta Investments Inc.4 shared
    Wellington Management3 shared
    Cormorant Asset Management3 shared
    SR One3 shared
    OrbiMed3 shared
    Medicxi3 shared
    HBM Healthcare Investments3 shared
    Astellas Venture Management3 shared
    RiverVest Venture Partners3 shared
    Canaan Partners3 shared
    Vertis SGR3 shared
    Vesper Holding3 shared

    Last updated: 7 October 2026